What are incretins, and how will they influence the management of type 2 diabetes?

Lawrence Blonde, Julio Rosenstock, Curtis Triplitt

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

OBJECTIVE: To review the pathophysiology of type 2 diabetes (T2DM), the role of incretins, the potential of incretin-based therapies to address unmet therapeutic needs in T2DM, and the potential impact this will have on the contribution of managed care pharmacy to diabetes therapy. SUMMARY: Diabetes, the fifth leading cause of death by disease in the United States, costs approximately $132 billion per year in direct and indirect medical expenses. According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, a majority of diabetes patients do not achieve target A1C levels with their current treatment regimens. Advances in understanding the pathophysiologic abnormalities underlying the metabolic dysfunctions associated with T2DM are leading to the development of new treatment approaches and new therapeutic classes of drugs. Novel incretin-based therapies currently available, and in late-stage development, are among those showing the greatest promise for addressing the unmet needs of traditional therapies. Copyright

Original languageEnglish (US)
Pages (from-to)S2-S12
JournalJournal of Managed Care Pharmacy
Volume12
Issue number7 SUPPL. A
StatePublished - Sep 1 2006

Keywords

  • DPP-4. Managed care
  • GLP-1
  • Incretin
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacy
  • Pharmaceutical Science
  • Health Policy

Fingerprint Dive into the research topics of 'What are incretins, and how will they influence the management of type 2 diabetes?'. Together they form a unique fingerprint.

Cite this